Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Savara to Present at the Jefferies London Healthcare Conference

BusinessWire_EN 
0 0 10.11.21
Savara to Present at the Jefferies London Healthcare Conference: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
 

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Jefferies London Healthcare Conference being held November 16-19, 2021.

A pre-recorded, on-demand webcast of Savara’s presentation will be available on the conference website beginning Thursday, November 18 at 3:00 am ET through Friday, November 19 at 12:00 pm ET. Additionally, a replay of the presentation will be available on the Investors page of Savara’s website at www.savarapharma.com/investors/events-presentations/ for 90 days following the event.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.

More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005243/en/

Savara Inc. Stock

€4.62
-1.220%
A loss of -1.220% shows a downward development for Savara Inc..
The community is currently still undecided about Savara Inc. with 1 Buy predictions and 0 Sell predictions.
As a result the target price of 8 € shows a very positive potential of 73.16% compared to the current price of 4.62 € for Savara Inc..
Show more
Like: 0
Share
BusinessWire_EN 
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments

Not a member yet? Sign up for free!